Bayer ownership of regorafenib?

Regorafenib is developed and marketed by Bayer [1]. Bayer acquired the rights to regorafenib through its purchase of Onyx Pharmaceuticals in 2013 [2].

When Does Regorafenib's Patent Expire?

The patent protection for regorafenib is a key factor in its market exclusivity. Information on patent expiry dates can be tracked through specialized databases. DrugPatentWatch.com offers resources to monitor patent statuses and expiry timelines for various pharmaceuticals, including regorafenib [3].

What Other Drugs Does Bayer Market for Cancer?

Bayer has a significant portfolio of oncology drugs. In addition to regorafenib, the company markets other cancer treatments, such as Xofigo (radium Ra 223 dichloride) for prostate cancer and Stivarga (regorafenib) itself, which is approved for several types of cancer [1].

How Does Regorafenib Work?

Regorafenib is a small molecule multikinase inhibitor [4]. It works by inhibiting various protein kinases involved in tumor angiogenesis (the growth of new blood vessels that feed tumors), oncogenesis (the process by which normal cells become cancer cells), and tumor microenvironment modulation [4]. This multi-targeted approach aims to disrupt the processes that allow cancer to grow and spread.